Pfizer Reports observational study Data for Baricitinib in Hidradenitis suppurativa

Pfizer today announced observational study results for Baricitinib in patients with Hidradenitis suppurativa. The study demonstrated that Baricitinib achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Hidradenitis suppurativa and support the continued development of Baricitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Baricitinib was consistent with previous observations, with no new safety signals identified.